癌症是全球死亡的主要原因之一。癌症对公共卫生的负担日益被广泛认识。肺癌的发病率和死亡率都位居各类癌症之首。早期筛查的普及、靶向治疗的出现以及免疫治疗的发展，都显著改善了肺癌患者的整体预后。然而，目前的情况并不令人鼓舞，存在一些患者治疗效果欠佳以及晚期肺癌患者预后极差等问题。由于其强大的免疫调节能力，胸腺肽类药物在肿瘤治疗中被广泛使用。大量研究已经证明了胸腺肽类药物在肺癌治疗中的有效性，充分展示了胸腺肽类药物在肺癌治疗中的潜力和未来。本文对胸腺肽类药物在肺癌临床研究和胸腺肽类药物在抗肺癌机制的基础研究进行系统总结和分析，并提出未来的研究方向。版权所有© 2023 刘和陸。

Cancer is one of the leading causes of death worldwide. The burden of cancer on public health is becoming more widely acknowledged. Lung cancer has one of the highest incidence and mortality rates of all cancers. The prevalence of early screening, the emergence of targeted therapy, and the development of immunotherapy have all significantly improved the overall prognosis of lung cancer patients. The current state of affairs, however, is not encouraging, and there are issues like poor treatment outcomes for some patients and extremely poor prognoses for those with advanced lung cancer. Because of their potent immunomodulatory capabilities, thymosin drugs are frequently used in the treatment of tumors. The effectiveness of thymosin drugs in the treatment of lung cancer has been demonstrated in numerous studies, which amply demonstrates the potential and future of thymosin drugs for the treatment of lung cancer. The clinical research on thymosin peptide drugs in lung cancer and the basic research on the mechanism of thymosin drugs in anti-lung cancer are both systematically summarized and analyzed in this paper, along with future research directions.Copyright © 2023 Liu and Lu.